HMGB1 promotes ERK-mediated mitochondrial Drp1 phosphorylation for chemoresistance through RAGE in colorectal cancer

Chih-Yang Huang1,2, Shu-Fen Chiang3, William Tzu-Liang Chen4, Tao-Wei Ke4, Tsung-Wei Chen5, Ying-Shu You3, Chen-Yu Lin3, K. S. Clifford Chao3 and Chih-Yang Huang6,7,8,9

Abstract
Dysfunctional mitochondria have been shown to enhance cancer cell proliferation, reduce apoptosis, and increase chemoresistance. Chemoresistance develops in nearly all patients with colorectal cancer, leading to a decrease in the therapeutic efficacies of anticancer agents. However, the effect of dynamin-related protein 1 (Drp1)-mediated mitochondrial fission on chemoresistance in colorectal cancer is unclear. Here, we found that the release of high-mobility group box 1 protein (HMGB1) in conditioned medium from dying cells by chemotherapeutic drugs and resistant cells, which triggered Drp1 phosphorylation via its receptor for advanced glycation end product (RAGE). RAGE signals ERK1/2 activation to phosphorylate Drp1 at residue S616 triggering autophagy for chemoresistance and regrowth in the surviving cancer cells. Abolishment of Drp1 phosphorylation by HMGB1 inhibitor and RAGE blocker significantly enhance sensitivity to the chemotherapeutic treatment by suppressing autophagy. Furthermore, patients with high phospho-Drp1Ser616 are associated with high risk on developing tumor relapse, poor 5-year disease-free survival (DFS) and 5-year overall survival (OS) after neoadjuvant chemoradiotherapy (neoCRT) treatment in locally advanced rectal cancer (LARC). Moreover, patients with RAGE-G82S polymorphism (rs2070600) are associated with high phospho-Drp1Ser616 within tumor microenvironment. These findings suggest that the release of HMGB1 from dying cancer cells enhances chemoresistance and regrowth via RAGE-mediated ERK/Drp1 phosphorylation.

Introduction
Colorectal cancer (CRC) is one of the leading cause of death worldwide1, accounting for approximately 9.7% of all cancer cases and approximately 8.5% of cancer deaths. Currently, the major chemotherapy drugs for the treatment of CRC include oxaliplatin (OXP), 5-fluorouracil (5-FU) and irinotecan (CPT-11). However, a considerable proportion of CRC patients develop local recurrence and distant metastasis within 5 years after surgical treatment. The overall survival of CRC patients remains poor with a median of 12–18 months, and the response to chemotherapy is only 50%2. Moreover, most metastatic CRC patients develop resistance to OXP as the cancer progresses within 8 months3.

Mitochondria are organelles that provide most of the energy to nearly all cells because of their synthesis of ATP via oxidative phosphorylation. Mitochondria are key organelles for cellular homeostasis, which is regulated by the following dynamic networks: fusion and fission4. Fusion is mediated by Mitofusin-1 and Mitofusin-2 (Mfn1 and Mfn2) and optic atrophy 1 (Opa1) proteins located at...
the outer and inner mitochondrial membranes, respectively. Fission is mediated by dynamin-related protein 1 (Drp1), which is a cytosolic protein that is recruited to the surface of mitochondria during activation, leading to mitochondrial fragmentation. Cumulative evidence has revealed that unbalanced mitochondrial dynamics dysregulate key cellular processes, potentially contributing to tumorigenesis, including lung, bladder, breast, and colon cancers. An imbalance in the expression of Drp1/Mfn is associated with excess mitochondrial fission and impaired mitochondrial fusion, which are important for the cell cycle progression. Recently, the mitogen-activated protein kinase (MAPK) pathway has been shown to result in an increased mitochondrial fragmentation and promote tumor growth and chemoresistance via the phosphorylation of the mitochondrial protein Drp1 at serine 616 by extracellular signal-regulated kinase 2 (ERK 2) in several cancers. However, to date, the molecular mechanisms by which the dysregulated mitochondrial dynamics contribute to cancer cell survival remain unclear.

High-mobility group box 1 protein (HMGB1) is a highly conserved nuclear protein that functions as a chromatin-binding factor that bends DNA and promotes access to transcriptional protein assemblies on specific targets. In addition to its intra-nuclear role, HMGB1 functions as an extracellular signaling molecule. Released HMGB1 mediates diverse responses by binding to several receptors, including the receptor for advanced glycation end products (RAGEs) and toll-like receptors (TLR)-2 and 4, which are known to display increased ligand binding to their respective receptors. Furthermore, the expression of RAGE is closely associated with a significant increase in the downstream signaling pathway for autophagy and chemoresistance could be a candidate therapeutic target for new treatment strategies in colorectal cancer.

Materials and methods

Cell culture and reagents

The human colorectal cancer cell lines SW480, SW620, LoVo and LoVo-OXR were cultivated in RPMI 1640 growth medium supplemented with 10% fetal bovine serum (Invitrogen, California, USA) at 37 °C under a humidified atmosphere of 5% CO2 and 95% air.

To prepare the conditioned medium (CM), the cells were washed and incubated with a serum-free medium for 2 h when sub-confluent. The medium was discarded, and the cells were incubated with a serum-free medium again. After 48 h, the CM was harvested and centrifuged to remove debris, filtered through a 0.22 μm filter, and stored at −20 °C until use.

Antibodies and reagents

The antibodies used in this study were as follows: anti-β-actin (sc-8432, Santa Cruz, CA, USA), anti-ERK1/2 (sc-135900, Santa Cruz, CA, USA), anti-p-ERK1/2 (sc-7383, Santa Cruz, CA, USA), anti-MFN1 (sc-50330, Santa Cruz, CA, USA), anti-RAGE (sc-365154, Santa Cruz, CA, USA), anti-MFN2 (sc-100560, Santa Cruz, CA, USA), anti-OPA1(sc-393296, Santa Cruz, CA, USA), anti-phospho-Drp1Ser616 (#3455, Cell Signaling Technology, MA, USA), anti-phospho-Drp1Ser637 (#6319, Cell Signaling Technology, MA, USA), anti-p62 (#39749, Cell Signaling Technology, MA, USA), anti-LC3 (#3868, Cell Signaling Technology, MA, USA), anti-HMGB1 (#3935, Cell Signaling Technology, MA, USA) and anti-Drp1 (#3935, Cell Signaling Technology, MA, USA) and anti-p62 (sc-39749, Cell Signaling Technology, MA, USA). All secondary antibodies (HRP-conjugated anti-rabbit, anti-mouse and anti-goat) were purchased from Santa Cruz Biotechnology. The lentivirus carrying shRNAs against RAGE, HMGB1, Drp1, MFN1 and OPA1 were obtained from the National Core Facility for Manipulation of Gene Function by RNAi, miRNA, miRNA sponges, and CRISPR/Genomic Research Center, Academia Sinica. The recombinant HMGB1 proteins, HMGB1 inhibitor quercetin were purchased from Sigma (St. Louis, MO, USA).
RAGE inhibitor FPS-ZM1 was purchased from Merck (Temecula, CA, USA).

Western blot analysis
The conditioned medium was collected by ultrafiltration using a Microcon filter (10,000-Da cutoff; Millipore, MA, USA) to purify the secreted protein. Either the total lysates (30 μg) or subcellular fractions (10 μg) were separated via 6–12% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto a PVDF membrane (GE Healthcare, Amersham, UK)27. The membranes were blocked with 5% non-fat milk and probed with specific antibodies overnight at 4 °C. Horse-radish peroxidase (HRP)-conjugated secondary antibodies (1:10,000, GE Healthcare, Amersham, UK) and the Immobilon Western Chemiluminescent HRP Substrate (Millipore, MA, USA) were used. A densitometric analysis of the western blots was performed using an AlphaImager2200 digital imaging system (Digital Imaging System, CA, USA). The digital images were processed using Adobe Photoshop 7.0. Each blot was stripped using Restore Western Blot Stripping Buffer (Pierce, IO, USA) to incubate with the other antibodies. The results were assessed using Image J software (NIH, MD, USA).

Assessment of cell growth and apoptosis, and mitochondria morphology
The cell growth was assessed using an MTT assay. Apoptosis and necrosis were assessed using the apoptosis/necrosis detection kit (Enzo Life Sciences, Plymouth Meeting, USA). According to the kit, the apoptotic and necrotic cells were labeled fluorescently by annexin V-EnzoGold and 7-AAD, respectively. The cells (2000) were observed to determine apoptosis or necrosis under a fluorescence microscope. The experiments were performed in triplicate. Lactate dehydrogenase C (LDH) and Terminal deoxynucleotidyl transferase (TdT)-mediated dUTP-biotin nick end labeling (TUNEL) were also performed.

Cells were stained with MitoTracker Red (MTR, Life Technologies #M7512). Cells were stained with the 100 nM MTR in completed medium for 30 min at 37 °C, after which the media was replaced for imaging.

Animal model
Athymic nude BALB/c mice (male, 4-weeks-old) were maintained according to the institutional guidelines approved by the China Medical University Institutional Animal Care and Use Committee. The serum HMGB1 level was examined on day 9. LoVo, LoVoOXR, SW480-vector, SW480-Drp1WT, SW480-Drp1S616E (1 × 106 cells/mouse) were suspended in Matrigel matrix with 50% serum-free DMEM, and injected subcutaneously into the flank of each mouse. The tumor volume, body weight and survival time were measured at various time intervals throughout the study. The tumor volumes were calculated according to the formula (width 2 × length)/2. The mice were sacrificed at the termination of the experiments, and the serum and tumor tissues from representative mice were collected for lysis, subjected to the immunoblotting analysis and stained by immunohistochemistry.

Enzyme-linked immunosorbent assay (ELISA)
The mouse blood was rapidly centrifuged at 500 × g for 4 min at 4 °C. The supernatant was used as the serum. The HMGB1 in the serum was measured using ELISA kit (Shinostet, Tokyo, Japan, and Abnova, Taipei City, Taiwan). ELISA was performed according to manufacturer's instructions. The experiment was repeated three times.

Patient selection, clinical staging, treatment, and pathological evaluation
Between 2006 and 2014, patients with locally advanced rectal cancer were treated at the China Medical University Hospital. Patients with biopsy-proven, locally advanced rectal cancer [cT3-4 or cN+ by endorectal ultrasonography (EUS), computed tomography (CT), or magnetic resonance imaging (MRI)] who were treated with preoperative chemoradiotherapy followed by radical resection at the China Medical University Hospital were the study cohorts. The study was reviewed and approved by the Internal Review Board (IRB) of the China Medical University Hospital [Protocol number: CMUH105-REC2-072]. Patients with concurrent distant metastasis or concurrent inflammatory bowel disease, hereditary colorectal cancer syndromes, concurrent malignancy, emergent surgery, prior history of radiotherapy to the pelvis, or prior history of malignancy were excluded. The tumors were staged according to the American Joint Committee on Cancer (AJCC) staging system.

The patients were treated with chemoradiotherapy at a median radiotherapy dose of 50.4 Gy and concurrent fluoropyrimidine-based chemotherapy (mainly single-agent infusional capecitabine). The age ranged from 31 to 90 years. Surgery, including low anterior resection, proctectomy with coloanal reconstruction, abdominoperineal resection, or multivisceral rectal resection using total mesorectal excision principles, was performed 6–8 weeks after the completion of chemoradiotherapy. Adjuvant chemotherapy was recommended for patients with metastatic lymph node(s) in the surgical specimen and consisted of infusional fluorouracil or capecitabine for a period of 4–6 months.

The pathological staging of the resected specimen was performed after resection in accordance with the guidelines of the College of American Pathologists, and the histopathological diagnosis was performed by pathologists specializing in gastrointestinal cancer. A pathological
complete response (pCR) was defined as the absence of viable adenocarcinoma cells in the surgical specimens (ypT0N0). The complete response (cCR) classification included specimens with acellular mucin pools without viable tumor cells.

Construction of tissue microarray (TMA)

Tissue microarrays were constructed from biopsies from 106 pair-matched pre-neoCRT and post-neoCRT rectal cancer patients (Table S1). One hundred and six pre-neoCRT biopsies and 93 [13 tumor regression grade 4 (TRG 4)] post-neoCRT surgical specimens were evaluated. The areas of the tumor were marked on hematoxylin & eosin (H & E) stained slides. The corresponding area on the matching paraffin block (donor block) was then identified and marked. We used the AutoTiss 10C system (EverBio Technology, Inc., Taipei, Taiwan) to remove the tissue core from these areas on the donor blocks, which were placed into the recipient block in a precisely arrayed fashion. The diameter of the punches was 2 mm. A maximum of 60 punches were placed on one single block. The sample sections (cut via a microtome) were then mounted on capillary-gap slides (Dako, Hamburg, Germany) and baked overnight.

Immunohistochemistry

The 3μm-thick TMA slides were individually stained with horseradish peroxidase-conjugated avidin biotin complex (ABC) from the Vectastain Elite ABC Kit (Vector Laboratories, Burlingame, CA) and NovaRed chromogen (Vector Laboratories, Burlingame, CA) and counterstained with hematoxylin. Positive staining for Drp1 and p-Drp1 was detected in the cytoplasm. The Drp1 or p-Drp1 staining patterns were evaluated in the sections according to the proportion of positively stained tumor cells under a microscope (OLYMPUS BX53, Tokyo, Japan). The intensity of the staining was evaluated, and five fields were used in the evaluation. The pathologists estimated the number of immunopositive cells. The staining intensity was scored as follows: a score of 0 indicated no color; light red was scored as 1; purple-red was scored as 2; and dark-red was scored as 3. The percentage of positive cells was scored as follows: a score of 0 was assigned when the positive tumor cell proportion was 10%; 1 point was assigned when the positive cell proportion ranged from 10 to 25%; 2 points were assigned when the positive cell proportion ranged from 26 to 50%; and 3 points were assigned when the positive cell proportion ranged from 51% to 100. The sum of the two scores served as the staining score. Using score of 3 as a cutoff, the immunostains were defined as “low” for scores from 0 to 3 and as “high” for scores from 4 to 9.

RAGE germ-line single-nucleotide polymorphism (SNP) analysis

Genomic DNA from rectal cancer patients was extracted from the FFPE tissue using a QuickExtract™ FFPE DNA Extraction Kit (Epicenter, WI, USA). For the SNP genotyping, 10 ng to total genomic DNA were used for the PCR amplification using the following specific primers: 5’-RAGE G82S (5’- ATTTGGATCCCCGTCACCTG TG -3’) and Biotin-3’- RAGE G82S (5’- GCCTGGCACCGGAAAAATC -3’).

The biotinylated PCR products were immobilized into streptavidin-coated super paramagnetic Dynabeads M280-streptavidin. The sequencing primers and RAGE-G82S-Seq (5’-CGTGTCCITTCCCCAAC-3’) were annealed to the DNA templates according to the manufacturer’s instructions (PSQk 96MA instrument, Qiagen).

Statistical analysis

The statistical analysis was performed using SAS statistical software, version PC 9.4 (SAS Institute, Cary, NC, USA). A two-sided p-value at significance level of 0.05 was reported for all tests. The between-group comparisons were performed using Student’s t-test, Pearson chi-square test and Fisher’s exact test. A Cox regression analysis was performed to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) for the univariate and multivariate models. The influential factors affecting the survival rate of the patients with rectal cancer were adjusted in the Cox models—including sex (female versus male), age (<65 vs. ≥65), TRG (3–4 vs. 1–2), clinical response (good response vs. poor response), and pN stage (positive vs. negative). The Kaplan–Meier estimation method was used to assess the five-year overall survival and disease-free survival. The survival time was defined as the time from surgery to death.

Results

Mitochondrial fission protein Drp1 is hyperactivated upon cytotoxic insults and promotes chemoresistance

By comparing the mitochondria dynamics between LoVo and oxaliplatin (OXP)-resistant LoVo cells, we found that mitochondria morphology was dramatic changed in LoVoOXR cells (Fig. 1a). We then aim to identify the mitochondrial proteins that are involved in chemoresistance in CRC. By analyzing the LoVoWT and LoVoOXR cell lines, we found that the knockdown of the mitochondrial fission proteins OPA1 and MFN1 did not sensitize the LoVoOXR cells to oxaliplatin (Fig. 1a). The knockdown efficiency was shown in Fig. S1A. Only knockdown of the mitochondrial fission protein Drp1 sensitized both the LoVoWT and LoVoOXR cells to OXP, suggesting that Drp1 might influence chemosensitivity in CRC (Fig. 1a). We then investigated the
Drp1 expression and phosphorylated status following exposure to chemotherapeutic drugs. A strikingly elevated phosphorylation of activated Drp1 (Ser616) was observed following the chemotherapeutic drug OXP treatment (Fig. 1b) but there is no variation on mitochondrial proteins MFN1 and MFN2 upon OXP treatment, suggesting that only Drp1 may participate in the chemoresistance via phosphorylation status. We then evaluated the phosphorylation status of Drp1 in well-characterized chemoresistant and metastatic colorectal cancer cell lines. By immunoblotting results, we found that Drp1 S616 phosphorylation were also significantly upregulated in LoVoOXR and SW620 cell lines. Moreover, the high levels of extracellular HMGB1 and phosphorylation of ERK1/2 were found in the OXP-resistant LoVoOXR (compared to LoVoWT) and metastatic SW620 (compared to SW480, Fig. 1c).

Recent studies have shown that mitochondrial fission via Drp1 significantly promoted cell survival by increasing autophagy, which promoted resistance to apoptosis and induced chemoresistance. The immunoblotting results showed that Drp1 and phospho-Drp1S616 were remarkably upregulated following diverse chemotherapeutic drug treatments, such as OXP, capecitabine (CAP, the pro-drug of 5-FU) and irinotecan (CPT-11) (Fig. 1d, Fig. S1B, C). Moreover, the amount of the mitochondrial autophagy adapter protein p62 was decreased and LC3-II was increased in response to chemotherapeutic drugs, implying that the chemotherapeutic drugs may induce autophagy to promote chemoresistance in CRC (Fig. 1d). Anticancer agents OXP, CAP, and CPT-11 also significantly promoted the HMGB1 expression in CRC (Fig. 1d).

To confirm the Drp1 phosphorylation promotes chemoresistance, we silenced Drp1 by lentivirus carrying shRNA against Drp1. Indeed, knockdown of Drp1 increased the chemosensitivity of LoVoOXR cells to...
chemotherapeutic drugs, promoting the cell death (Fig. 1e) and decreasing cell viability (Fig. 1f). Moreover, treatment with Drp1 inhibitor Mdivi-1 also increased the sensitivity to OXP either LoVoWT or LoVoOXR (Fig. S1D). These results indicated that Drp1-mediated mitochondrial fission notably promoted chemoresistance in CRC cells.

Highly phosphorylated Drp1 may promote chemoresistant tumor growth through HMGB1/RAGE signaling pathway

To verify the role of Drp1 on chemoresistant CRC in vivo, we inoculated athymic nu/nu mice with LoVoWT and LoVoOXR. Tumors derived from LoVoWT grew more slowly compared with those derived from LoVoOXR (Fig. 2a). We observed that the LoVoOXR showed hyperactivated Drp1 levels in vivo (Fig. 2a). Moreover, the immunoblotting results showed that the phosphorylated Drp1Ser616 protein level was highly recruited to the mitochondrial fraction in the tumor derived from LoVoOXR cells (Fig. 2b). These results show that Drp1 is important for modulating chemoresistance via mitochondria fission in CRC cells in vivo. Moreover, immunohistochemistry analysis showed that the level of RAGE and the distribution of HMGB1 in LoVoOXR group was altered. Cytosolic translocation of HMGB1 was significantly increased in LoVoOXR group, suggesting that HMGB1 was translocated from nucleus into cytoplasm, and then secreted into plasma. Consistent with this observation, high serum HMGB1 was detected in LoVoOXR group (Fig. 2c). Moreover, the results of immunohistochemistry also showed that RAGE, the receptor of HMGB1, was greatly upregulated in LoVoOXR group (Fig. 2c).
group (Fig. 2c). Immunoblotting results from resected tumor tissues also revealed high HMGB1 level, active ERK1/2 and phospho-Drp1S616 in LoVo\textsuperscript{OXR} group (Fig. 2d). We also observed an increased level of LC3-II expression and decrease p62 level in LoVo\textsuperscript{OXR} tumor comparison with control LoVo\textsuperscript{WT} tumor (Fig. 2d). Moreover, the mitochondrial fusion protein MFN2 was not influenced between these two tumors. These results implied the critical role of HMGB1 in modulating the chemosensitivity via ERK-mediated Drp1 CRC in vitro and in vivo.

**HMGB1 triggered ERK-mediated Drp1 phosphorylation via RAGE in CRC**

To confirm the relationship between HMGB1 and Drp1 phosphorylation, we treated the CRC cells with recombinant HMGB1 and observe its influence on ERK/Drp1 signaling. We found that ERK and Drp1 were activated by the HMGB1 recombinant protein in both SW480 and LoVo cell lines (Fig. 3a). Inhibition of RAGE by FPS-ZM1\textsuperscript{31} blocked the HMGB1-induced Drp1 phosphorylation and ERK1/2 activation in dose-dependent manner (Fig. 3b). Furthermore, enforced expression of wt-RAGE sensitized the HMGB1-induced Drp1 phosphorylation (Fig. 3c). Similarly, knockdown of RAGE by lentivirus-based shRNA significantly alleviated HMGB1-induced Drp1 phosphorylation and ERK1/2 activation (Fig. 3d).

Furthermore, addition of HMGB1 dramatically influences the mitochondria morphology and increases conversion of LC3-I to LC3-II and decreases p62 level (Fig. 3e). Treatment with Drp1 inhibitor Mdivi-1, which is a small molecular inhibitor of Drp1\textsuperscript{32}, mitigates HMGB1-induced Drp1 phosphorylation, mitochondria morphology alteration, LC3 conversion and p62 levels decrease.

To identify whether HMGB1 was responsible for chemoresistance via Drp1 phosphorylation, we pre-treated with recombinant HMGB1 for 1 h prior to addition of OXP (Fig. 3f). Pre-incubation of HMGB1 significantly alleviated OXP-induced cell viability decrease. But blockade of RAGE by FPS-ZM1 or inhibition of Drp1 by Mdivi-1 neutralized the OXP-induced cell death. Addition of HMGB1 prior to OXP treatment also reduced the OXP-induced caspase-3 activity. However, the caspase-3 activity was decreased by FPS-ZM1 and Mdivi-1, suggesting that HMGB1 is required for chemoresistance to OXP via Drp1. Taken together, these results indicated that the extracellular HMGB1 promotes ERK activation-mediated Drp1 phosphorylation resulting in tumor growth and chemoresistance via RAGE.

**Inhibition of Drp1 alleviated chemotherapeutic drugs-induced autophagy and chemoresistance in vitro and in vivo**

Consistent with previous results, we found that Drp1 inhibitor Mdivi-1 significantly alleviated the CAP-induced Drp1 phosphorylation, conversion of LC3 I to LC3II and decrease in p62 (Fig. 5a). To determine Drp1 phosphorylation is critical for drug resistance in tumor cells, we constructed a gain-of-function Drp1 containing both S616E (to mimic activating phosphorylation) and
S637A (to block inhibitory phosphorylation) mutations. Enforced expression of Drp1<sup>S616E</sup> accelerated the CAP-induced p62 decrease and LC3-II conversion (Fig. 5b). These results demonstrate that hyperactivated Drp1 is essential for chemoresistance via mitochondrial fission and autophagy.

To further explore the effect of the mitochondrial dynamics on cell survival in CRC cells, we inoculated athymic nude BALB/c mice with SW480 tumor cells that stably expressed hyperactivated Drp1<sup>S616E</sup> or wild-type Drp1. The growth of the Drp1<sup>S616E</sup> tumor cells was significantly faster than that of the wild-type Drp1–transfected tumors (Fig. 5c). We observed that increased autophagy in the resected tumor transfected with wild-type Drp1 and Drp1<sup>S616E</sup> in vivo (Fig. 5d). The level of p62 was dramatically decreased and the ratio of LC3-II/I was increased. But the Drp1<sup>S616E</sup>-transfected tumor cells displayed more autophagy (Fig. 5d). These results showed that Drp1-mediated mitochondrial fission notably promoted autophagy and chemoresistance in CRC cells.
Hyperactivated Drp-1 within tumor microenvironment is associated with poor 5-years disease-free survival (DFS) and 5-year overall survival in LARC patients

To determine the clinical relevance of these findings, we performed a combination of tissue analysis studies. We performed an immunohistochemistry analysis of Drp1 and phospho-Drp1 Ser616 on 106 pair-matched pre-neoCRT biopsies and post-neoCRT surgical tissues in LARC patients using a tissue microarray (TMA, Fig. 6a). These patients were received the preoperative neoadjuvant chemoradiotherapy (neoCRT). The median dose of radiation was 50.4 Gy in 28 fractions. The concurrent chemotherapy was fluorouracil-based in 42% of the patients and capecitabine (CAP) in 58% of the patients. After neoCRT treatment, 12% (13/106) of the patients had a complete response, while 82% (93/106) of the patients...
had a partial response based on the tumor regression grade (TRG). The clinicopathological characteristics are presented in Table S1.

Patients with high level of Drp1 have no significant correlation with these parameters. But patients with high level of phospho-Drp1Ser616 had high risk on tumor relapse within 5 years \((p = 0.0073)\) (Table S1). Moreover, patients with high phospho-Drp1Ser616 showed increased risk on poor 5-years disease-free survival (DFS, \(p = 0.01\), Fig. 6b) and 5-years overall survival (OS, \(p = 0.01\), Fig. 6c) in LARC before neoCRT treatment (Table 1).

Furthermore, in the post-neoCRT surgical specimens \((n = 93)\), we found that the patients with the high phospho-Drp1Ser616 still showed high risk on poor DFS \((p = 0.0003, \text{Fig. 6d})\) and 5-year OS \((p = 0.002, \text{Fig. 6e})\) in LARC. These results indicated that phospho-Drp1Ser616 was significantly associated with the risk of developing tumor relapse after neoCRT treatment, suggesting that phospho-Drp1Ser616 contributes to treatment resistance and metastasis in LARC.

Prognostic relevance of hyperactivated Drp-1 in LARC patients receiving neoadjuvant chemoradiotherapy (neoCRT) treatment

In the univariate analysis, the patients with high level of phospho-Drp1Ser616 had an increased risk on poor 5-year OS \((HR = 3.164, 95\% CI 1.238–8.089, p = 0.016, \text{Table 2})\). In the multivariate analysis, the patients with high phospho-Drp1Ser616 in the tumor microenvironment had an increased risk on poor 5-year OS \((HR = 3.821, 95\% CI 1.459–10.008, p = 0.006, \text{Table 2})\). These results indicated that phospho-Drp1Ser616 is a significant prognostic factor for survival outcome in LARC patients who treated with neoCRT. Moreover, after neoCRT treatment, we found that the high phospho-Drp1Ser616 was significantly observed in the metastatic lymph nodes (Fig. 6a), and associated with tumor relapse (Table S2).

Furthermore, we found a substantial proportion of RAGE-G82S polymorphism (36/106 [34%]) in patients with LARC. Patients with RAGE-G82S polymorphism did not correlated with high phospho-Drp1Ser616 before neoCRT treatment \((p = 0.84, \text{Table 3})\). But patients with
RAGE-G82S polymorphism displayed high phospho-Drp1 \(^{Ser616}\) after neoCRT treatment \((p = 0.05\), Table 3\), suggesting that patients with RAGE-G82S polymorphisms may have increased Drp1 activation to promote chemoresistance and tumor regrowth after chemoradiotherapy treatment, leading to poor survival outcome in LARC. Taken together, these results demonstrated that HMGB1 released from dying cancer cells after neoCRT may enhance regrowth and metastasis of remnant cancer cells via RAGE-ERK-Drp1 activation.

**Discussion**

Most CRC patients develop resistance to chemotherapy drugs, such as oxaliplatin, which is a significant challenge in the treatment of colon cancer. This phenomenon has been attributed to different mechanisms, including dysfunctional membrane transport, resistance to apoptosis, and DNA repair mechanisms. In this study, we showed that Drp1-mediated mitochondria fission, which results in autophagy, is a significant contributor to drug resistance in CRC. Following chemotherapy treatment, the release of HMGB1 is induced, and HMGB1 can exert autocrine or paracrine effects that activate Drp1 and lead to chemoresistance and tumor recurrence (Fig. 6f). Moreover, the inhibition of mitochondria fission via Drp1, the blockage of the release of HMGB1 or the blockage of the HMGB1 receptor RAGE enhance the sensitivity of anti-cancer agents in CRC.

Cancer cells respond to chemotherapy in a variety of ways, ranging from the activation of survival pathways to the initiation of cell death. Consistent with previous studies that identified a cytoprotective role of autophagy,
increased autophagy is observed following exposure to chemotherapy drugs. Here, we reported that mitochondria fission by Drp1 hyperactivation is required for autophagy and chemoresistance. Because Drp1 has been shown to be involved in several cellular processes, such as mitochondrial energetics to sustain tumor development, stem cell maintenance, promotion of metastasis and cell proliferation, Drp1-driven mitochondrial fission has been considered a vital factor in the context of tumorigenesis. Several emerging studies have focused on the relationship between mitochondrial dynamics and cell fate determination. Serasinghe et al. reported that ERK-mediated Drp1 S616 phosphorylation in mitochondrial division was necessary for RAS-induced transformation. The disruption of Drp1 activity was shown to promote mitochondrial fusion and inhibit tumor growth. Moreover, recent studies have shown that mitochondrial fission via Drp1 significantly promoted cell survival by increasing autophagy, resulting in a resistance to apoptosis in HCC and chemoresistance in acute lymphoblastic leukemia (ALL). Cai et al. revealed that the remarkable elevation of the activating phosphorylation of Drp1 at S616 decreased the mitochondrial ROS levels, resulted in a pro-glycolytic metabolism shift and increased drug resistance. Collectively, these results and our present findings indicate that Drp1-mediated mitochondrial dynamics are associated with increasing autophagy, resulting in resistance to cell death and chemoresistance.

HMGB1 has been reported as a DAMP for immunogenic cell death (ICD) during chemotherapy and radiotherapy, and its release from necrotic cancer cells may activate the innate immune system to promote host anticancer immunity. However, extracellular HMGB1 is known to act as a growth factor that activates mitogen-activated protein kinase (MAPK) and thereby enhances the regrowth, metastasis, and chemoresistance of remnant cancer cells that survived prior chemotherapy via RAGE. The role of chemotherapy-associated HMGB1 is thought to depend on the balance of these different effects of HMGB1. Indeed, the knockdown of RAGE or HMGB1 increased cell death and restored the chemosensitivity of the cancer cells in vivo and in vitro, indicating that this knockdown may lead to the induction of cancer progression and drug resistance. The ability of released HMGB1 to promote chemoresistance in cancer cells, such as neuroblastoma, lung adenocarcinoma, prostate cancer, CRC, and leukemia, is reportedly due to autophagy. Consistently, we found that OXP, CAP, and CPT-11 promote the enhanced expression and secretion of HMGB1 in human colorectal cancer cells. HMGB1 has been reported to be a critical regulator of autophagy. Cytosolic HMGB1 is an inducer of starvation-mediated autophagy by binding to Beclin 1 in colorectal cancer. In addition, extracellular HMGB1 induces autophagy via its receptor RAGE in colorectal and pancreatic cancer cells. HMGB1-mediated autophagy modulates the sensitivity of colorectal cancer cells to Oxaliplatin via the MEK/ERK signaling pathway. This hypothesis is supported by our findings in which HMGB1 was associated with autophagy and chemoresistance via RAGE/MEK/ERK/Drp1 in colorectal cancer. Moreover, we found that the expression of Drp1 and p-Drp1 was positively correlated with patients carrying germ-line single-nucleotide polymorphisms (SNPs) of RAGE with G82S (rs2070600) after neoCRT treatment. RAGE-G82S has been reported to exhibit potentially enhanced ligand-binding affinity, such as to

### Table 1 Clinicopathologic parameters with 5-year DFS and 5-year OS in pre-neoCRT biopsy of LARC (n = 106)

| Variable | All patients (n = 106) | Total cases | DFS | 5-years (%) | p value | 5-years OS | p value |
|----------|-----------------------|-------------|-----|-------------|---------|------------|---------|
| cN stage |                       | 106         | 71  | 73          | 0.37    | 0.65       |         |
| Negative | 50                    | 76          |     | 82          |         |            |         |
| Positive | 56                    | 66          |     | 78          |         |            |         |
| pN stage |                       |             |     |             | 0.05*   | 0.02*      |         |
| Negative | 74                    | 77          |     | 88          |         |            |         |
| Positive | 32                    | 59          |     | 66          |         |            |         |
| Clinical response |            | 0.78       |   | 0.07       |         |            |         |
| Good response |                 | 56         | 71  | 85          |         |            |         |
| Poor response |                | 50         | 70  | 72          |         |            |         |
| TRG |                       |             |     | 0.37       | 0.06    |            |         |
| Good response |                 | 74         | 73  | 84          |         |            |         |
| Poor response |                | 32         | 65  | 68          |         |            |         |
| Drp1 (pre-neoCRT) |          | 0.78       |   | 0.77       |         |            |         |
| Low |                    | 61         | 73  | 80          |         |            |         |
| High |                    | 45         | 69  | 78          |         |            |         |
| p-Drp1 Ser616 (pre-neoCRT) |          |             |    | 0.01* |         | 0.01*      |         |
| Low |                    | 55         | 82  | 89          |         |            |         |
| High |                    | 51         | 59  | 69          |         |            |         |

n: number; DFS: 5-years DFS; OS: 5-years OS; p values for DFS and OS were calculated by log-rank test; DFS: disease-free survival; OS: overall survival; cN stage: positive (Stage 1 + 2) vs. negative (Stage 0); pN stage: positive (Stage 1a + 1b + 2) vs. negative (Stage 0 + X); Clinical response: good response (complete response and partial response) vs. poor response (stable disease and progression disease); TRG: good response (TRG 1–4) vs. poor response (TRG 1–2); Drp1 and p-Drp1: high (grade 2–4) vs. low (grade 0–1); Kalpan-Meier method was used for survival analysis; SE: standard error
HMGB1, which supports our finding in which HMGB1 triggered Drp1 phosphorylation via RAGE.

Our results suggested that patients with RAGE-G82S polymorphisms may have high affinity for the ligand, such as HMGB1, which activates ERK1/2 to phosphorylate Drp1 for mitochondria fission and autophagy. Eventually, Drp1-mediated mitochondria fission promotes chemoresistance and tumor regrowth, leading to poor survival outcome in LARC.

The data reported here indicate the potential of extracellular HMGB1 released from colorectal cancer cells to exert a paracrine effect on surviving cancer cells enabling them to resist chemoradiotherapy. Targeting the receptor RAGE and the downstream effector Drp1 in cancer cells may prevent or inhibit the development of drug resistance. In contrast, there is evidence that chemotherapeutic drug-induced HMGB1 can mediate the activation of innate immunity and tumor clearance. Thus, caution must be exercised because of the potential positive and negative aspects of HMGB1 expression during different phases of tumor development and treatment.

These results showed that the potential of extracellular HMGB1 released from colorectal cancer cells to exert a paracrine effect on surviving cancer cells enabling them to resist chemoradiotherapy via RAGE-ERK-Drp1 signaling pathway.

**Table 2** Univariate and multivariate analysis of 5-year OS in LARC

| Variable                  | Cases | Pre-neoCRT (n = 106) | Post-neoCRT (n = 93) |
|---------------------------|-------|----------------------|----------------------|
| pN stage (positive vs. negative) |       | 2.611 (0.025*)       | 2.605 (0.033*)       |
| Clinical response (poor response vs. good response) |       | 2.161 (0.082)        | 2.206 (0.105)        |
| TRG (poor response vs. good response) |       | 2.115 (0.08)         | 2.068 (0.104)        |
| Drp1 (high vs. low)       |       | 1.136 (0.766)        | 1.219 (0.658)        |
| p-Drp1Ser616 (high vs. low) |       | 3.164 (0.016*)       | 3.065 (0.022*)       |

**Table 3** Correlation between p-Drp1 and RAGE SNP in pre-neoCRT biopsies and post-neoCRT surgical tissues of LARC

| Variable                  | Cases | Pre-neoCRT (n = 106) | Post-neoCRT (n = 93) |
|---------------------------|-------|----------------------|----------------------|
| RAGE                      |       | 0.84                 | 0.05*                |
| WT                        | 70    | 1                    | 1                    |
| Variant                   | 36    | 1.121 (0.5015–2.507) | 2.478 (1.025–5.989)  |

Acknowledgements
The experiments and data analysis were performed using the Medical Research Core Facilities Center, Office of Research & Development at China Medical University, Taichung, Taiwan. We are grateful for the tissue microarray (TMA) support from the Translation Research Core, China Medical University Hospital. The lentivirus carrying shRNAs were obtained from the National Core Facility for Manipulation of Gene Function by RNAi, miRNA, miRNA sponges, and CRISPR/Genomic Research Center, Academia Sinica and supported by the National Core Facility Program for Biotechnology Grants of MOST (MOST 104-2319-B-001-001-). This work was supported by grants from the Ministry of Health and Welfare, Taiwan (MOHW107-TDU-B-212-123004), Health and welfare surcharge of tobacco products, China Medical University Hospital.
Cancer Research Center of Excellence (MOHW107-TDU-B-121-114024, Taiwan) and China Medical University Hospital, Taiwan (DMR-107-126).

Author details
1Translation Research Core, China Medical University Hospital, China Medical University, 40402 Taichung, Taiwan. 2Department of Nutrition, HungKuang University, 43302 Taichung, Taiwan. 3Cancer Center, China Medical University Hospital, China Medical University, 40402 Taichung, Taiwan. 4Department of Colorectal Surgery, China Medical University Hospital, China Medical University, 40402 Taichung, Taiwan. 5Department of Pathology, China Medical University Hospital, China Medical University, 40402 Taichung, Taiwan. 6School of Chinese Medicine, China Medical University Hospital, 40402 Taichung, Taiwan. 7School of Chinese Medicine, China Medical University, 40402 Taichung, Taiwan. 8Department of Health and Nutrition Biotechnology, Asia University, 41354 Taichung, Taiwan. 9Medical Research Center For Exosomes and Mitochondria Related Diseases, China Medical University Hospital, China Medical University, 40402 Taichung, Taiwan

Author contributions
C.-Y.H. and S.-F.C. conducted and performed the experiments; W.T.-L.C., T.-W.K. and W.-W.C. analyzed and wrote the manuscript.

Conflict of interest
The authors declare that they have no conflict of interest.

Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information accompanies this paper at (https://doi.org/10.1038/s41419-018-1019-6).

Received: 2 May 2018 Revised: 9 July 2018 Accepted: 27 August 2018

Published online: 26 September 2018

References
1. Siegel, R. L. et al. Colorectal cancer statistics, 2017. Cancer J. Clin. 67, 177–193 (2017).
2. Adlard, J. W., Richman, S. D., Seymour, M. T. & Quincke, P. Prediction of the response of colorectal cancer to systemic therapy. Lancet Oncol. 3, 75–82 (2002).
3. Goldberg, R. M. et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 22, 23–30 (2004).
4. Wang, K. C., Brooks, D. A., Botting, K. J. & Morrison, J. L. IGF-IR-mediated signaling results in hyper trophy of cultured cardiomyocytes from fetal sheep. Biol. Reprod. 86, 183 (2012).
5. Zhao, J. et al. Mitochondrial dynamics regulates migration and invasion of breast cancer cells. Oncogene 32, 4814–4824 (2013).
6. Santacane, S., Herzig, S. & Martinou, J. C. Mitochondrial dynamics and cancer. Semin. Cancer Biol. 19, 50–56 (2009).
7. Reehman, J. et al. Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer. Faseb. J. 26, 2175–2186 (2012).
8. Jin, B. et al. Anti-tumor efficacy of mitofusin-2 in urinary bladder carcinoma. Med. Oncol. 28(Suppl 1), S373–S380 (2011).
9. Inoue-Yamauchi, A. & Oda, H. Depletion of mitochondrial division factor DRP1 causes increased apoptosis in human colon cancer cells. Biochem. Biophys. Res. Commun. 421, 81–85 (2012).
10. Huang, Q. et al. Increased mitochondrial fission promotes autophagy and hepaticcellular carcinoma cell survival through the ROS-modulated coordinated regulation of the NRF2 and TP53 pathways. Autophagy 12, 999–1014 (2016).
11. Cai, J. et al. ERK/Drp1-dependent mitochondrial fission is involved in the MSC-induced drug resistance of T-cell acute lymphoblastic leukemia cells. Cell Death Dis. 7, e2459 (2016).
12. Prieto, J. et al. Early ERK1/2 activation promotes DRP1-dependent mitochondrial fission necessary for cell reprogramming. Nat. Commun. 7, 11124 (2016).
13. Kashatus, J. A. et al. ERK2 phosphorylation of Drp1 promotes mitochondrial fission and MAPK-driven tumor growth. Mol. Cell 57, 537–551 (2015).
14. Fu, L. et al. SIRT4 inhibits malignancy progression of NSCLCs, through mitochondrial dynamics mediated by the ERK-Drp1 pathway. Oncogene 36, 2724–2736 (2017).
15. Luo, Y. et al. High mobility group box 1 released from necrotic cells enhances regrowth and metastasis of cancer cells that have survived chemotherapy. Eur. J. Cancer 49, 741–751 (2013).
16. Lee, H. et al. Diagnostic significance of serum HMGB1 in colorectal carcinomas. PLoS One 7, e34318 (2012).
17. Liu, W. et al. HMGB1-mediated autophagy modulates sensitivity of colorectal cancer cells to oxaliplatin via MEK/ERK signaling pathway. Cancer Biol. Ther. 16, 511–517 (2015).
18. Pan, B. et al. HMGB1-mediated autophagy promotes doxorubicin resistance in human lung adenocarcinoma. Mol. Cancer 13, 165 (2014).
19. Amornsupak, K. et al. Cancer-associated fibroblasts induce high mobility group box 1 and contribute to resistance to doxorubicin in breast cancer cells. BMC Cancer 14, 955 (2014).
20. Zhang, R. et al. Interference with HMGB1 increases the sensitivity to chemotherapy drugs by inhibiting HMGB1-mediated cell autophagy and inducing cell apoptosis. Tumour Biol. 36, 8585–8592 (2015).
21. Huang, J. et al. HMGB1 promotes drug resistance in osteosarcoma. Cancer Res. 72, 230–238 (2012).
22. Kunisaya, H. et al. Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J. Pathol. 196, 163–170 (2002).
23. Saashita, T., Akama, Y., Fujii, K. & Kunisaya, H. Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas. Virchows. Arch. 446, 411–415 (2005).
24. Hofmann, M. A. et al. RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun. 3, 123–135 (2002).
25. Huttunen, H. J. & Rautala, H. Amphoterin as an extracellular regulator of cell motility from discovery to disease. J. Intern. Med. 255, S51–S66 (2004).
26. Xia, W. et al. Association of RAGE polymorphisms and cancer risk: a meta-analysis of 27 studies. Med. Oncol. 32, 442 (2015).
27. Lin, T. Y., Fan, C. W., Maa, M. C. & Leu, T. H. Lipopolysaccharide-promoted proliferation of Caco-2 cells is mediated by c-Src induction and ERK activation. Biomedicine 5, 5 (2015).
28. Chao, K. S. C. et al. Acquired immunity trumps yph+ and TRG as the sole prognostic biomarker for locally advanced rectal cancer (LARC) treated with neoadjuvant chemoradiation therapy (NeoCRT). Int. J. Radiat. Oncol. Biol. Phys. 96, S108 (2016).
29. Wang, X. et al. RSF-1 overexpression determines cancer progression and drug resistance in cervical cancer. Biomedicine 8, 4 (2018).
30. Huang, C. Y. et al. Cytosolic high-mobility group box protein 1 (HMGB1) and/or PD-1+ TILs in the tumor microenvironment may be contributing prognostic biomarkers for patients with locally advanced rectal cancer who have undergone neoadjuvant chemoradiotherapy. Cancer Immunol. Immunother. 67, 551–562 (2018).
31. Zhan, D., Guo, L. & Zheng, L. Inhibition of the receptor for advanced glycation promotes proliferation and repair of human periodontal ligament fibroblasts in response to high glucose via the NF-kappaB signaling pathway. Arch. Oral Biol. 87, 86–93 (2017).
32. Tanaka, A. & Youle, R. J. A chemical inhibitor of DRP1 uncouples mitochondrial fission and apoptosis. Mol. Cell 29, 409–410 (2008).
33. Li, X. et al. Quercetin protects mice from ConA-induced hepatitis by inhibiting HMGB1-LIR expression and down-regulating the nuclear factor kappa B pathway. Inflammation 39, 96–106 (2016).
34. Tang, D. et al. Quercetin prevents LPS-induced high-mobility group box 1 release and proinflammatory function. Am. J. Respir. Cell Mol. Biol. 41, 651–660 (2009).
35. Kondo, Y., Kanazawa, T., Sawaya, R. & Kondo, S. The role of autophagy in cancer development and response to therapy. Nat. Rev. Cancer 5, 726–734 (2005).
36. Amaravadi, R. K. et al. Principles and current strategies for targeting autophagy for cancer treatment. Clin. Cancer Res. 17, 654–666 (2011).
37. Wieder, S. Y. et al. Activation of the mitochondrial fragmentation protein DRP1 correlates with BRAF(V600E) melanoma. J. Invest. Dermatol. 135, 2544–2547 (2015).
38. Serasinghe, M. N. et al. Mitochondrial division is requisite to RAS-induced transformation and targeted by oncogenic MAPK pathway inhibitors. Mol. Cell 57, 521–536 (2015).
39. Czura, C. J., Wang, H. & Tracey, K. J. Dual roles for HMGB1: DNA binding and cytokine. J. Endotoxin Res. 7, 315–321 (2001).
40. Bhawal, U. K. et al. Association of expression of receptor for advanced glycation end products and invasive activity of oral squamous cell carcinoma. Oncology 69, 246–255 (2005).
41. Taguchi, A. et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405, 354–360 (2000).
42. Kunyasu, H., Chihara, Y. & Kondo, H. Differential effects between amphoterin and advanced glycation end products on colon cancer cells. Int. J. Cancer 104, 722–727 (2003).
43. Kunyasu, H., Chihara, Y. & Takahashi, T. Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol. Rep. 10, 445–448 (2003).
44. Wang, L., Zhang, H., Sun, M., Yin, Z. & Qian, J. High mobility group box 1-mediated autophagy promotes neuroblastoma cell chemoresistance. Oncol. Rep. 34, 2969–2976 (2015).
45. Zhou, J. et al. HMGB1 induction of clusterin creates a chemoresistant niche in human prostate tumor cells. Sci. Rep. 5, 15085 (2015).
46. Liu, L. et al. HMGB1-induced autophagy contributes to drug resistance. Leukemia 25, 881–892 (2010).
47. Liu, L. et al. HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene 29, 5299–5310 (2010).
48. Osawa, M. et al. De-N-glycosylation or G82S mutation of RAGE sensitizes its interaction with advanced glycation end products. Biochim. Biophys. Acta 1770, 1468–1474 (2007).